Reviva Pharma Announces Positive Data From DDI Study Of CYP3A4 Enzyme Effect On Brilaroxazine

RTTNews | 881 dagar sedan
Reviva Pharma Announces Positive Data From DDI Study Of CYP3A4 Enzyme Effect On Brilaroxazine

(RTTNews) - Biopharmaceutical company Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced Thursday positive data from its recently completed clinical drug-drug interaction (DDI) study investigating the potential effect of CYP3A4 enzyme on brilaroxazine in healthy subjects.

The CYP3A4 enzyme plays a pivotal role in helping the body metabolize and remove small foreign molecules and is primarily found in the liver and intestine.

DDI evaluation is a critical clinical pharmacology study required by the U.S. Food and Drug Administration (FDA) and other regulatory agencies globally for approving a new drug to market.

Brilaroxazine is a serotonin/dopamine modulator in late-stage clinical development for the treatment of schizophrenia.

Following FDA guidelines, the DDI clinical study was designed to evaluate the drug interaction effect of a strong CYP3A4 inhibitor or inducer when co-administered with brilaroxazine in healthy volunteers.

Reviva believes that brilaroxazine's clinical safety is further reinforced with the positive results of this DDI study, which found no clinically significant interaction when combined with a CYP3A4 inhibitor.

Brilaroxazine is currently being evaluated in RECOVER, a pivotal global Phase 3, randomized, double-blind, placebo-controlled, multicenter study designed to assess the safety and efficacy of brilaroxazine in approximately 400 patients with acute schizophrenia compared to placebo. Topline data is expected in mid-2023.

For More Such Health News, visit rttnews.com

read more
E.ON Confirms Outlook After Higher Q1 Adj. Earnings

E.ON Confirms Outlook After Higher Q1 Adj. Earnings

German utility E.ON SE reported Wednesday a significant increase in its first-quarter adjusted earnings and Group EBITDA with growth in all three core segments. Further, the firm affirmed its guidance for 2025 and its outlook through 2028. On the XETRA in Germany, E.ON shares were gaining around 1.36 percent.
RTTNews | 38 minuter sedan
Yen Rises Against Majors

Yen Rises Against Majors

The Japanese yen strengthened against other major currencies in the European session on Wednesday.
RTTNews | 3h 2minuter sedan
FTSE 100 Flat As Stocks Move In Tight Range

FTSE 100 Flat As Stocks Move In Tight Range

U.K. stocks are mostly subdued in lackluster trade on Wednesday as investors react to a mixed batch of earnings announcements, and await more economic data from the U.S., and clarity about Trump administration's stance on tariffs with regard to European countries.
RTTNews | 3h 37minuter sedan
CAC 40 Down 0.66%; Bouygues Rises Sharply On Earnings

CAC 40 Down 0.66%; Bouygues Rises Sharply On Earnings

French stocks are exhibiting weakness on Wednesday, snapping a four-session winning streak, as investors focus on earnings and other corporate news, and await more economic data for directional clues. Some profit taking is also contributing to market's weakness.
RTTNews | 3h 58minuter sedan
Sensex, Nifty End Choppy Session Modestly Higher

Sensex, Nifty End Choppy Session Modestly Higher

Indian shares ended modestly higher on Wednesday as signs of easing retail inflation sparked hopes for more rate cuts from the Reserve Bank of India in coming months.
RTTNews | 4h 3minuter sedan
European Shares Drift Lower In Lackluster Trade

European Shares Drift Lower In Lackluster Trade

European stocks were slightly lower in cautious trade on Wednesday while the dollar extended losses as benign U.S. inflation data prompted traders to pare back Fed rate cut bets for this year.
RTTNews | 5h 12minuter sedan